Market Intel: Liquid Biopsy – Ready For Prime Time?

Liquid biopsy is a rapidly developing noninvasive technology for the early detection of cancer. Multiple companies have entered clinical testing, using mostly blood to detect circulating tumor cells and/or circulating tumor DNA. But urine and even cerebral spinal fluid are promising liquids too. Regardless of the fluid, testing costs a fraction of a traditional, invasive tissue biopsy and offers much quicker results.

Pathology. Medical Concept. - Image

Could 2019 be the tipping point for the adoption of liquid biopsy?

Many companies in the space hope so, although it remains to be seen how the information can best be integrated into the total management of patients. Len Lichtenfeld, interim chief medical and scientific officer for the American Cancer Society, said the advantages of liquid biopsy are still being developed

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Medtech Insight